{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:56:15Z","timestamp":1782946575546,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1A2C2007430"],"award-info":[{"award-number":["2021R1A2C2007430"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02521-4","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T11:37:54Z","timestamp":1765971474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fadraciclib, a CDK2\/CDK9 inhibitor, shows efficacy in biliary tract cancer and synergistic potential with olaparib and JQ1 based on MCL1 expression"],"prefix":"10.1186","volume":"23","author":[{"given":"Jae-Min","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ah-Rong","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Seok","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Hee","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoojin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sea Young","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su In","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeesun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"issue":"10272","key":"2521_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh D-Y, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344.","journal-title":"Lancet"},{"issue":"9","key":"2521_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"2521_CR3","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1007\/s00535-020-01712-9","volume":"55","author":"C Xie","year":"2020","unstructured":"Xie C, McGrath NA, Monge Bonilla C, Fu J. Systemic treatment options for advanced biliary tract carcinoma. J Gastroenterol. 2020;55(10):944\u201357.","journal-title":"J Gastroenterol"},{"issue":"24","key":"2521_CR4","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1038\/s41388-022-02347-1","volume":"41","author":"TA Constantin","year":"2022","unstructured":"Constantin TA, Greenland KK, Varela-Carver A, Bevan CL. Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer. Oncogene. 2022;41(24):3303\u201315.","journal-title":"Oncogene"},{"issue":"1","key":"2521_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccell.2018.03.023","volume":"34","author":"ME Klein","year":"2018","unstructured":"Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A. CDK4\/6 inhibitors: the mechanism of action may not be as simple as once thought. Cancer Cell. 2018;34(1):9\u201320.","journal-title":"Cancer Cell"},{"key":"2521_CR6","doi-asserted-by":"publisher","first-page":"212579","DOI":"10.7573\/dic.212579","volume":"8","author":"F Serra","year":"2019","unstructured":"Serra F, Lapidari P, Quaquarini E, Tagliaferri B, Sottotetti F, Palumbo R. Palbociclib in metastatic breast cancer: current evidence and real-life data. Drugs Context. 2019;8:212579.","journal-title":"Drugs Context"},{"issue":"9","key":"2521_CR7","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1158\/2159-8290.CD-20-1114","volume":"11","author":"AC Mandigo","year":"2021","unstructured":"Mandigo AC, Yuan W, Xu K, Gallagher P, Pang A, Guan YF, et al. RB\/E2F1 as a master regulator of cancer cell metabolism in advanced disease. Cancer Discov. 2021;11(9):2334\u201353.","journal-title":"Cancer Discov"},{"issue":"7","key":"2521_CR8","doi-asserted-by":"publisher","first-page":"e0234103","DOI":"10.1371\/journal.pone.0234103","volume":"15","author":"S Frame","year":"2020","unstructured":"Frame S, Saladino C, MacKay C, Atrash B, Sheldrake P, McDonald E, et al. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLoS ONE. 2020;15(7):e0234103.","journal-title":"PLoS ONE"},{"issue":"10","key":"2521_CR9","first-page":"4096","volume":"6","author":"Y-Z Shi","year":"2000","unstructured":"Shi Y-Z, Hui A-M, Li X, Takayama T, Makuuchi M. Overexpression of Retinoblastoma Protein Predicts Decreased Survival and Correlates with Loss of p16INK4 Protein in Gallbladder Carcinomas1. Clin Cancer Res. 2000;6(10):4096\u2013100.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"2521_CR10","first-page":"2637","volume":"127","author":"W Wang","year":"2014","unstructured":"Wang W, Yin X, Li G, Yi J, Wang J. Expressions of farnesoid X receptor and myeloid cell leukemia sequence 1 protein are associated with poor prognosis in patients with gallbladder cancer. Chin Med J Engl. 2014;127(14):2637\u201342.","journal-title":"Chin Med J Engl"},{"issue":"1","key":"2521_CR11","doi-asserted-by":"publisher","first-page":"18489","DOI":"10.1038\/s41598-020-75578-5","volume":"10","author":"H Saqub","year":"2020","unstructured":"Saqub H, Proetsch-Gugerbauer H, Bezrookove V, Nosrati M, Vaquero EM, de Semir D, et al. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2\/5\/9. Sci Rep. 2020;10(1):18489.","journal-title":"Sci Rep"},{"issue":"2","key":"2521_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","volume":"27","author":"VV Senichkin","year":"2020","unstructured":"Senichkin VV, Streletskaia AY, Gorbunova AS, Zhivotovsky B, Kopeina GS. Saga of Mcl-1: regulation from transcription to degradation. Cell Death Differ. 2020;27(2):405\u201319.","journal-title":"Cell Death Differ"},{"issue":"10","key":"2521_CR13","doi-asserted-by":"publisher","first-page":"e108371","DOI":"10.1371\/journal.pone.0108371","volume":"9","author":"RN Booher","year":"2014","unstructured":"Booher RN, Hatch H, Dolinski BM, Nguyen T, Harmonay L, Al-Assaad AS, et al. MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis. PLoS ONE. 2014;9(10):e108371.","journal-title":"PLoS ONE"},{"issue":"3","key":"2521_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","volume":"19","author":"JS Ross","year":"2014","unstructured":"Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014;19(3):235\u201342.","journal-title":"Oncologist"},{"issue":"36","key":"2521_CR15","doi-asserted-by":"publisher","first-page":"58007","DOI":"10.18632\/oncotarget.11157","volume":"7","author":"AR Nam","year":"2016","unstructured":"Nam AR, Kim JW, Cha Y, Ha H, Park JE, Bang JH, et al. Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget. 2016;7(36):58007\u201321.","journal-title":"Oncotarget"},{"key":"2521_CR16","doi-asserted-by":"publisher","first-page":"e06535","DOI":"10.7554\/eLife.06535","volume":"4","author":"H Lu","year":"2015","unstructured":"Lu H, Xue Y, Yu GK, Arias C, Lin J, Fong S, et al. Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism. Elife. 2015;4:e06535.","journal-title":"Elife"},{"issue":"4","key":"2521_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.molcel.2005.06.027","volume":"19","author":"MK Jang","year":"2005","unstructured":"Jang MK, Mochizuki K, Zhou M, Jeong H-S, Brady JN, Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell. 2005;19(4):523\u201334.","journal-title":"Mol Cell"},{"issue":"4","key":"2521_CR18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.molcel.2005.06.029","volume":"19","author":"Z Yang","year":"2005","unstructured":"Yang Z, Yik JHN, Chen R, He N, Jang MK, Ozato K, et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005;19(4):535\u201345.","journal-title":"Mol Cell"},{"issue":"1","key":"2521_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bbcan.2017.11.001","volume":"1869","author":"J Cheng","year":"2018","unstructured":"Cheng J, Guo J, Wang Z, North BJ, Tao K, Dai X, et al. Functional analysis of Cullin 3 E3 ligases in tumorigenesis. Biochim Biophys Acta Rev Cancer. 2018;1869(1):11\u201328.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2521_CR20","doi-asserted-by":"crossref","unstructured":"Bricelj A, Steinebach C, Kuchta R, G\u00fctschow M, Sosi\u010d I. E3 ligase ligands in successful PROTACs: an overview of syntheses and linker attachment points. Front Chem. 2021;9:707317","DOI":"10.3389\/fchem.2021.707317"},{"issue":"37","key":"2521_CR21","doi-asserted-by":"publisher","first-page":"15073","DOI":"10.1021\/jacs.1c04841","volume":"143","author":"J Wei","year":"2021","unstructured":"Wei J, Meng F, Park K-S, Yim H, Velez J, Kumar P, et al. Harnessing the E3 ligase KEAP1 for targeted protein degradation. J Am Chem Soc. 2021;143(37):15073\u201383.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"2521_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1158\/1078-0432.CCR-18-0284","volume":"25","author":"X Song","year":"2019","unstructured":"Song X, Liu X, Wang H, Wang J, Qiao Y, Cigliano A, et al. Combined CDK4\/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma. Clin Cancer Res. 2019;25(1):403\u201313.","journal-title":"Clin Cancer Res"},{"key":"2521_CR23","doi-asserted-by":"crossref","unstructured":"Arora M, Bogenberger JM, Abdelrahman AM, Yonkus J, Alva-Ruiz R, Leiting JL, et al. Synergistic combination of cytotoxic chemotherapy and cyclin dependent kinase 4\/6 inhibitors in biliary tract cancers. Hepatology. 2022;75(1):43\u201358.","DOI":"10.1002\/hep.32102"},{"issue":"2","key":"2521_CR24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.21873\/anticanres.14035","volume":"40","author":"T Nakano","year":"2020","unstructured":"Nakano T, Go T, Nakashima N, Liu D, Yokomise H. Overexpression of antiapoptotic MCL-1 predicts worse overall survival of patients with non-small cell lung cancer. Anticancer Res. 2020;40(2):1007\u201314.","journal-title":"Anticancer Res"},{"issue":"1","key":"2521_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2005.09.010","volume":"44","author":"W Sieghart","year":"2006","unstructured":"Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul-Rockenschaub S, et al. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol. 2006;44(1):151\u20137.","journal-title":"J Hepatol"},{"key":"2521_CR26","doi-asserted-by":"publisher","first-page":"100672","DOI":"10.1016\/j.blre.2020.100672","volume":"44","author":"AH Wei","year":"2020","unstructured":"Wei AH, Roberts AW, Spencer A, Rosenberg AS, Siegel D, Walter RB, et al. Targeting MCL-1 in hematologic malignancies: rationale and progress. Blood Rev. 2020;44:100672.","journal-title":"Blood Rev"},{"issue":"12","key":"2521_CR27","doi-asserted-by":"publisher","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","volume":"9","author":"CR Churi","year":"2014","unstructured":"Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS ONE. 2014;9(12):e115383.","journal-title":"PLoS ONE"},{"issue":"1","key":"2521_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41698-018-0064-z","volume":"2","author":"JM Bogenberger","year":"2018","unstructured":"Bogenberger JM, DeLeon TT, Arora M, Ahn DH, Borad MJ. Emerging role of precision medicine in biliary tract cancers. NPJ Precis Oncol. 2018;2(1):21.","journal-title":"NPJ Precis Oncol"},{"issue":"35","key":"2521_CR29","doi-asserted-by":"publisher","first-page":"59476","DOI":"10.18632\/oncotarget.19761","volume":"8","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Zhou L, Leng Y, Dai Y, Orlowski RZ, Grant S. Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget. 2017;8(35):59476\u201391.","journal-title":"Oncotarget"},{"issue":"6","key":"2521_CR30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/leu.2015.10","volume":"29","author":"GP Gregory","year":"2015","unstructured":"Gregory GP, Hogg SJ, Kats LM, Vidacs E, Baker AJ, Gilan O, et al. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. Leukemia. 2015;29(6):1437\u201341.","journal-title":"Leukemia"},{"issue":"6","key":"2521_CR31","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1128\/MCB.01426-14","volume":"35","author":"K Liang","year":"2015","unstructured":"Liang K, Gao X, Gilmore JM, Florens L, Washburn MP, Smith E, et al. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing. Mol Cell Biol. 2015;35(6):928\u201338.","journal-title":"Mol Cell Biol"},{"issue":"5","key":"2521_CR32","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s12276-020-0442-9","volume":"52","author":"SH Choi","year":"2020","unstructured":"Choi SH, Kim S, Jones KA. Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation. Exp Mol Med. 2020;52(5):762\u201371.","journal-title":"Exp Mol Med"},{"issue":"9","key":"2521_CR33","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","volume":"17","author":"SF Johnson","year":"2016","unstructured":"Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, et al. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer. Cell Rep. 2016;17(9):2367\u201381.","journal-title":"Cell Rep"},{"issue":"4","key":"2521_CR34","first-page":"1140","volume":"10","author":"J Li","year":"2020","unstructured":"Li J, Zhi X, Chen S, Shen X, Chen C, Yuan L, et al. CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer. Am J Cancer Res. 2020;10(4):1140\u201355.","journal-title":"Am J Cancer Res"},{"issue":"7","key":"2521_CR35","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/15384101.2017.1295177","volume":"16","author":"TC Nepomuceno","year":"2017","unstructured":"Nepomuceno TC, Fernandes VC, Gomes TT, Carvalho RS, Suarez-Kurtz G, Monteiro AN, et al. BRCA1 recruitment to damaged DNA sites is dependent on CDK9. Cell Cycle. 2017;16(7):665\u201372.","journal-title":"Cell Cycle"},{"issue":"1","key":"2521_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00432-023-05527-y","volume":"150","author":"Z Wang","year":"2024","unstructured":"Wang Z, Li W, Li F, Xiao R. An update of predictive biomarkers related to WEE1 inhibition in cancer therapy. J Cancer Res Clin Oncol. 2024;150(1):13.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2521_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41698-024-00787-4","volume":"9","author":"D Kim","year":"2025","unstructured":"Kim D, Chung H, Liu W, Jeong K, Ozmen TY, Ozmen F, et al. Cyclin E1\/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. NPJ Precis Oncol. 2025;9(1):3.","journal-title":"NPJ Precis Oncol"},{"key":"2521_CR38","doi-asserted-by":"crossref","unstructured":"Bradbury A, Zenke FT, Curtin NJ, Drew Y. The role of ATR inhibitors in ovarian cancer: investigating predictive biomarkers of response. Cells. 2022;11(15):2361.","DOI":"10.3390\/cells11152361"},{"issue":"1","key":"2521_CR39","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1038\/s41467-021-25904-w","volume":"12","author":"PA Konstantinopoulos","year":"2021","unstructured":"Konstantinopoulos PA, da Costa AABA, Gulhan D, Lee EK, Cheng S-C, Hendrickson AEW, et al. A replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat Commun. 2021;12(1):5574.","journal-title":"Nat Commun"},{"key":"2521_CR40","doi-asserted-by":"publisher","first-page":"216820","DOI":"10.1016\/j.canlet.2024.216820","volume":"589","author":"E Orhan","year":"2024","unstructured":"Orhan E, Velazquez C, Tabet I, Fenou L, Rodier G, Orsetti B, et al. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in triple negative breast cancer. Cancer Lett. 2024;589:216820.","journal-title":"Cancer Lett"},{"issue":"49","key":"2521_CR41","doi-asserted-by":"publisher","first-page":"84986","DOI":"10.18632\/oncotarget.18583","volume":"8","author":"N Moreno","year":"2017","unstructured":"Moreno N, Holsten T, Mertins J, Zhogbi A, Johann P, Kool M, et al. Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors. Oncotarget. 2017;8(49):84986\u201395.","journal-title":"Oncotarget"},{"key":"2521_CR42","doi-asserted-by":"crossref","unstructured":"Liu N, Ling R, Tang X, Yu Y, Zhou Y, Chen D. Post-translational modifications of BRD4: therapeutic targets for tumor. Front Oncol. 2022;12:847701.","DOI":"10.3389\/fonc.2022.847701"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02521-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T11:37:56Z","timestamp":1765971476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-025-02521-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2521"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02521-4","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted at the Institute for Experimental Animals, College of Medicine, Seoul National University (Seoul, South Korea) in accordance with institutional guidelines for experimental protocols approved from the Institutional Animal Care and Use Committee (IACUC) of Seoul National University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"530"}}